Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor: University of Cincinnati
Study ID: NCT07274787
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

NaviFUS System — DEVICE
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB. The NaviFUS System is indicated for use to enhance the permeability of conventionally administered therapeutic agents into targeted brain tissue to enhance their therapeutic effects.
Lumason — DRUG
The NaviFUS System is a FUS phased array system intended to transcranially deliver burst-mode ultrasound energy with the concurrent microbubble intravenous administration to temporally and locally open the BBB.
Bevacizumab — DRUG
In this proposed clinical investigation, the NaviFUS System will be used in conjunction with BEV in recurrent GBM patients.

Study Details

This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.